Virax Biolabs Group Limit...

1.12
0.02 (2.01%)
At close: Apr 02, 2025, 3:59 PM
1.11
-0.84%
After-hours: Apr 02, 2025, 08:00 PM EDT

Virax Biolabs Income Statement

Financials in USD. Fiscal year is April - March.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Period Ending Mar 31, 2024 Mar 31, 2023 Mar 31, 2022 Mar 31, 2021 Mar 31, 2020
Revenue 156.42K 8.56K n/a 123.82K 99.88K
Cost of Revenue 105.83K 9.93K n/a 133.25K 54.13K
Gross Profit 50.59K -1.36K n/a -9.43K 45.75K
Operating Income -6.5M -5.73M -1.73M -644.54K -651.24K
Interest Income n/a 15.47K 15.44K 28.64K 90.69K
Pretax Income -6.74M -5.46M -1.75M -672.91K -739.46K
Net Income -6.73M -5.46M -1.71M -650.98K -801.13K
Selling & General & Admin 4.59M 5.33M 1.3M 514.88K 609.99K
Research & Development 1.56M 397.11K 433.74K 120.22K 87K
Other Expenses 390.36K 290.47K n/a 266.00 2.47K
Operating Expenses 6.55M 5.73M 1.73M 635.1K 696.99K
Interest Expense 26.88K 15.47K 15.44K 28.64K 90.69K
Selling & Marketing Expenses n/a 26.62K 13.82K 57.2K 7.69K
Cost & Expenses 6.65M 5.74M 1.73M 768.36K 751.12K
Income Tax n/a -271 -1.77M -666.47K 61.67K
Shares Outstanding (Basic) 2.01M 1.06M 1.14M 1.14M 1.14M
Shares Outstanding (Diluted) 2.01M 1.06M 1.14M 1.14M 1.14M
EPS (Basic) -3.36 -5.13 -1.5 -0.57 -0.7
EPS (Diluted) -3.36 -5.13 -1.5 -0.57 -0.7
EBITDA -6.61M -5.44M -750 n/a -648.77K
EBIT -6.71M -5.44M -1.73M -644.27K -648.77K
Depreciation & Amortization 103.1K 1.00 1.73M 644.54K 651.24K